Nevertheless, understanding a drug's mechanism could guide drug development ... given that ErbB2 is the known target for the breast cancer drug herceptin, tumors can be screened for its presence ...

The new Herceptin formulation is now in phase 3 clinical trials, and if the program were successful, it would offer patients a convenient dosing form of the drug, which is currently given via ...

The mechanisms of action are complex and not ... [3] By blocking the HER2 receptor with trastuzumab (Herceptin™; Genentech, South San Francisco, CA, USA), the inhibition of these cancer-driving ...